Pulmonary arterial hypertension (PAH) is a lethal syndrome characterized by obstruction of the pulmonary vasculature due (in part) to idiopathic hyper-proliferation of pulmonary arterial smooth muscle cells (PASMC). Preliminary data suggest that this proliferative diathesis relates to excessive mitochondrial fission caused by activation of dynamin related protein 1 (DRP-1). In this proposal we will define the molecular basis for dysregulation of fission in human PAH and explore the nature of the link between a mitochondrial fission-fusion cycle and the cell cycle. We also evaluate whether the requirement of these hyper-proliferative cells for high rates of mitochondrial fission presents an Achilles hee that can be therapeutically targeted. Experiments are performed in human PAH PASMC and lungs and in experimental models (induced by monocrotaline or SU5416 + hypoxia). Preliminary data indicate that human PAH PASMC have fragmented mitochondria, largely due to increased fission. We have developed metrics that use mitochondrial-targeted, photoactivated, green fluorescent protein (mito-paGFP) and 2-photon confocal microscopy to quantify mitochondrial fission. Increased fission in PAH appears to result from phosphorylation of DRP-1 at Serine 616 by the key mitotic regulatory kinase, Cyclin B1- CDK1, thus linking fission and mitosis. Elevated cytosolic calcium in PAH also promotes DRP-1-mediated fission by: a) activation of calmodulin kinase and b) calcineurin-mediated dephosphorylation of an inhibitory form of DRP- 1 (Phos-Ser637). Thus, increased activity of calcineurin, cyclin B1-CDK1 and DRP-1 promote fission and proliferation in human PAH PASMC;conversely, DRP-1 inhibition (via the small molecule inhibitor, mdivi-1, or siDRP-1) decreases PASMC proliferation and, in the case of mdivi-1, regresses PAH in vivo. Hypothesis: Pathologic DRP-1 activation increases fission and promotes excessive PASMC proliferation in PAH. Corollary: DRP-1 inhibition prevents cell cycle progression, causing G2-M phase arrest. Anti-fission therapies may constitute an antiproliferative therapy for PAH.
Aim 1) Are DRP-1 activation and fission required for the hyperproliferation of PASMC in human PAH? Aim 2) Does post-translational DRP-1 modification regulate PASMC proliferation in PAH? Aim 3) Does inhibition of mitochondrial fission have therapeutic benefit in experimental PAH? Innovation and Impact: This proposal is innovative in recognizing that """"""""mitochondrial checkpoints"""""""", related to DRP-1 activation and fission, regulate cell cycle progression. The concept that mitochondrial fission is tightly linked to cell cycle progression via shared regulatory kinases is also novel. The discovery that inhibiting DRP-1 (directly or by targeting its regulatory kinases) is anti-proliferative offers a new, """"""""anti-fission profusion"""""""", therapeutic paradigm for PAH. The translational potential of this proposal is enhanced by careful correlation of results in rodent PAH models with findings in human PAH lungs/cells from a well-characterized cohort. This is the first study to exploit PAH's reliance on rapid fission to devise novel anti-fission, anti-proliferative therapies for PAH.
Pulmonary arterial hypertension (PAH) is a disease of the lung's blood vessels caused in part by excessive rates of vascular growth, leading to vascular obstruction and this places a strain on the right heart, causing disability and a 15% annual death rate due to right heart failure. We identified a mitochondrial abnormality in human PAH smooth muscle cells that causes them to grow rapidly, contributing to the blockage. In PAH the mitochondrial network is fragmented, a process called fission. Excess fission reflects increased activity of an enzyme called dynamin related protein (DRP-1). Inhibiting DRP-1 slows cell growth and reduces experimental PAH. We will define the cause of increased fission in PAH and explore a link between fission and mitosis that relates to a shared regulatory kinase, CDK1. Increased fission may present an Achilles heel for rapidly growing cells. The therapeutic potential of anti-fission drugs is tested in human PAH tissues/cells and in rodent models.
|Tian, Lian; Neuber-Hess, Monica; Mewburn, Jeffrey et al. (2017) Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension. J Mol Med (Berl) 95:381-393|
|Archer, Stephen L (2017) Pyruvate Kinase and Warburg Metabolism in Pulmonary Arterial Hypertension: Uncoupled Glycolysis and the Cancer-Like Phenotype of Pulmonary Arterial Hypertension. Circulation 136:2486-2490|
|Dunham-Snary, Kimberly J; Wu, Danchen; Sykes, Edward A et al. (2017) Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine. Chest 151:181-192|
|Dunham-Snary, Kimberly J; Hong, Zhigang G; Xiong, Ping Y et al. (2016) A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus. Pflugers Arch 468:43-58|
|Atkins, Kathleen; Dasgupta, Asish; Chen, Kuang-Hueih et al. (2016) The role of Drp1 adaptor proteins MiD49 and MiD51 in mitochondrial fission: implications for human disease. Clin Sci (Lond) 130:1861-74|
|Sharp, Willard W; Beiser, David G; Fang, Yong Hu et al. (2015) Inhibition of the mitochondrial fission protein dynamin-related protein 1 improves survival in a murine cardiac arrest model. Crit Care Med 43:e38-47|
|Ryan, John; Dasgupta, Asish; Huston, Jessica et al. (2015) Mitochondrial dynamics in pulmonary arterial hypertension. J Mol Med (Berl) 93:229-42|
|Hemnes, Anna R; Trammell, Aaron W; Archer, Stephen L et al. (2015) Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension. Circulation 131:401-9; discussion 409|
|Sharp, Willard W; Archer, Stephen L (2015) Mitochondrial dynamics in cardiovascular disease: fission and fusion foretell form and function. J Mol Med (Berl) 93:225-8|
|Dasgupta, A; Bowman, L; D'Arsigny, C L et al. (2015) Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Clin Pharmacol Ther 97:88-102|
Showing the most recent 10 out of 40 publications